---
figid: PMC3012004__nihms259273f2
figtitle: Sites of action for inhibitors and shRNAs in the EGFR-PI3K-Akt-mTOR pathway
organisms:
- NA
pmcid: PMC3012004
filename: nihms259273f2.jpg
figlink: /pmc/articles/PMC3012004/figure/F2/
number: F2
caption: Sites of action for inhibitors and shRNAs in the EGFR-PI3K-Akt-mTOR pathway.
  Agents that inhibit the EGFR-PI3K-Akt-mTOR pathway at multiple sites may contribute
  to anticancer effects in malignant glioma. Agents that inhibit only one target within
  the EGFR-PI3K-Akt-mTOR axis generally show only modest efficacy and fail to induce
  appreciable apoptosis. This disappointing efficacy stems in-part from multiple nodes
  of activation in the EGFR-PI3K-Akt-mTOR axis. For example, loss of PTEN activates
  PI3K signaling. A feedback loop between S6K and IRS-1 also lead to PI3K activation.
  Inhibition of the PI3K-Akt-mTOR pathway may also induce autophagy, enabling cancer
  cells to survive some small molecule inhibitors of this pathway
papertitle: 'Targeting the RTK-PI3K-mTOR Axis in Malignant Glioma: Overcoming Resistance.'
reftext: Qi-Wen Fan, et al. Curr Top Microbiol Immunol. ;347:279-296.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9622619
figid_alias: PMC3012004__F2
figtype: Figure
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
redirect_from: /figures/PMC3012004__F2
ndex: 23870769-deda-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3012004__nihms259273f2.html
  '@type': Dataset
  description: Sites of action for inhibitors and shRNAs in the EGFR-PI3K-Akt-mTOR
    pathway. Agents that inhibit the EGFR-PI3K-Akt-mTOR pathway at multiple sites
    may contribute to anticancer effects in malignant glioma. Agents that inhibit
    only one target within the EGFR-PI3K-Akt-mTOR axis generally show only modest
    efficacy and fail to induce appreciable apoptosis. This disappointing efficacy
    stems in-part from multiple nodes of activation in the EGFR-PI3K-Akt-mTOR axis.
    For example, loss of PTEN activates PI3K signaling. A feedback loop between S6K
    and IRS-1 also lead to PI3K activation. Inhibition of the PI3K-Akt-mTOR pathway
    may also induce autophagy, enabling cancer cells to survive some small molecule
    inhibitors of this pathway
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGFR
  - PIK3R1
  - PIK3R2
  - ARHGEF7
  - CBFA2T2
  - PPP1R13B
  - PPP1R12C
  - CUX1
  - SART3
  - PTEN
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PDK1
  - PDPK1
  - PDK2
  - PDK3
  - PDK4
  - IRS1
  - AKT1
  - AKT2
  - AKT3
  - TSC2
  - TSC1
  - CCL26
  - MTOR
  - RPTOR
  - RICTOR
  - MAPKAP1
  - MLST8
  - RPS6KB1
  - Egfr
  - Myb
  - Pi3K21B
  - Taf5
  - l(1)G0020
  - Taf4
  - Pi3K92E
  - Rpn2
  - Sap-r
  - Pten
  - Pi3K59F
  - Pi3K68D
  - Pdk1
  - Pdk
  - Akt
  - gig
  - Tsc1
  - Mtor
  - Tor
  - raptor
  - Crtc
  - rictor
  - RpS6
  - S6k
  - LY294002
  - BEZ235
  - Ser
  - Thr
  - Rapamycin
  - Cancer
---
